ADVM files 8-K, furnishes Q2 2025 earnings press release (Exhibit 99.1)

Rhea-AI Filing Summary

Adverum Biotechnologies reported that it has issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a corporate update. The press release is furnished as Exhibit 99.1, and the cover page of the report is presented in Inline XBRL as Exhibit 104.

The filing explicitly states that the information in the report and the exhibit is not deemed "filed" under the Exchange Act and will not be incorporated by reference into other SEC filings. The 8-K itself does not include the underlying financial figures; the detailed results are contained in the furnished press release.

Positive

• Press release furnished as Exhibit 99.1, providing the company's announced quarterly results and a corporate update.
• Inline XBRL cover page (Exhibit 104) included, supporting machine-readable disclosure formatting.

Negative

• No financial figures or metrics are included in the 8-K text itself; the filing relies on the furnished press release for substantive results.
• The company states the press release is not "filed" and will not be incorporated by reference, which limits statutory liability and may affect how the information is treated in subsequent filings.

Insights

Securities Analyst

TL;DR: Routine disclosure that furnishes a press release with quarter-end results; no financial data is included in the 8-K itself.

The filing is a standard Item 2.02 disclosure indicating the company furnished a press release announcing results for the quarter ended June 30, 2025. Because the 8-K contains no numeric results, its market impact depends entirely on the contents of Exhibit 99.1. The explicit statement that the materials are not "filed" and are not incorporated by reference limits statutory liabilities for the company. Investors must review the press release to assess material financial effects.

Corporate Governance Expert

TL;DR: Administrative disclosure that confirms transparency in communicating quarter-end results but preserves legal protections by not 'filing' the release.

The company followed routine disclosure practices by furnishing a press release as Exhibit 99.1 and providing an Inline XBRL cover page as Exhibit 104. The filing's language that the release is not deemed "filed" and will not be incorporated by reference is a common legal posture to limit liability exposure. This is procedural rather than material without the press release contents being evaluated.

false000150175600015017562025-08-122025-08-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

August 12, 2025

Date of Report (Date of earliest event reported)

Adverum Biotechnologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware			001-36579			20-5258327
(State or other jurisdiction of incorporation)			(Commission File Number)			(I.R.S. Employer Identification No.)

100 Cardinal Way

Redwood City, CA 94063

(Address of principal executive offices, including zip code)

(650) 656-9323

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐    Soliciting material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)

☐    Pre-commencement communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))

☐    Pre-commencement communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock

ADVM

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02    Results of Operations and Financial Condition.

On August 12, 2025, Adverum Biotechnologies, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025, and providing a corporate update. A copy of such press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this report, including the exhibit hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this report and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by Adverum Biotechnologies, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01    Financial Statements and Exhibits.

Exhibit No.						Description
99.1						Press Release dated August 12, 2025, announcing Adverum Biotechnologies, Inc. financial results for the quarter ended June 30, 2025, and providing a corporate update.
104						The cover page of this report has been formatted in Inline XBRL.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Adverum Biotechnologies, Inc.
Date: August 12, 2025			By:			/s/ Laurent Fischer
						Laurent Fischer, M.D. President and Chief Executive Officer

FAQ

What did Adverum (ADVM) disclose in this 8-K?

Adverum furnished a press release (Exhibit 99.1) announcing its financial results for the quarter ended June 30, 2025 and provided a corporate update.

Does the 8-K include the company's financial results?

No. The 8-K states the detailed financial figures are in the furnished press release; the filing itself does not contain the numeric results.

Is the press release considered "filed" with the SEC?

No. The company explicitly states the information in the report and exhibit is not deemed "filed" under the Exchange Act and will not be incorporated by reference.

Where can I find the press release mentioned in the 8-K?

The press release is furnished as Exhibit 99.1 to the Form 8-K; the cover page is provided in Inline XBRL as Exhibit 104.

Who signed the Form 8-K for Adverum?

Laurent Fischer, M.D., President and Chief Executive Officer is the signatory shown on the filing.